Antennova Presents Latest Phase I/II Data on ATN-022 in Advanced/Metastatic Gastric Cancer, Including an ORR of 42.9%, at ASCO GI 2025
BOSTON,Jan. 22,2025-- Antennova,a clinical-stage biotech company focused on oncology today announced the presentation of latest data from itsPhase I/II CLINCH study ongoing in China and Australia eval